Regulation and function of cyclic nucleotide phosphodiesterases in vascular smooth muscle and vascular diseases

Cyclic Nucleotide Phosphodiesterases in Health and Disease

Volumn , Issue , 2006, Pages 465-484

  Yan, Chen ^a   Nagel, David J ^a   Jeon, Kye Im ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 72449139582     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (102)

1. Soderling, S.H., and J.A. Beavo. 2000. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions. Curr Opin Cell Biol 12:174.
2. Chini, C.C., et al. 1997. Compartmentalization of cAMP signaling in mesangial cells by phosphodiesterase isozymes PDE3 and PDE4. Regulation of superoxidation and mitogenesis. J Biol Chem 272:9854.
3. Cheng, J., et al. 2004. Differential regulation of mesangial cell mitogenesis by cAMP phosphodiesterase isozymes 3 and 4. Am J Physiol Renal Physiol 287:F940.
4. Ding, B., et al. 2005. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: Implication in heart failure. Circulation 111:2469.
5. Zaccolo, M., and T. Pozzan. 2002. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science 295:1711.
6. Mongillo, M., et al. 2004. Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res 95:67.
7. Suga, S., et al. 1992. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of vascular natriuretic peptide system. J Clin Invest 90:1145.
8. Komatsu, Y., et al. 1992. Vascular natriuretic peptide. Lancet 340:622.
9. Aizawa, T., et al. 2003. Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Circ Res 93:406.
10. Koyama, H., et al. 2001. Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation. J Cell Physiol 186:1.
11. Rybalkin, S.D., and K.E. Bornfeldt. 1999. Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation. Thromb Haemost 82:424.
12. Lloyd-Jones, D.M., and K.D. Bloch. 1996. The vascular biology of nitric oxide and its role in atherogenesis. Annu Rev Med 47:365.
13. Ross, R. 1993. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362:801.
14. Pham, N., et al. 2000. The guanine nucleotide exchange factor CNrasGEF activates ras in response to cAMP and cGMP. Curr Biol 10:555.
15. Murad, F. 1996. The 1996 Albert Lasker Medical Research Awards. Signal transduction using nitric oxide and cyclic guanosine monophosphate. JAMA 276:1189.
16. Vandecasteele, G., et al. 2001. Cyclic GMP regulation of the L-type Ca(2+) channel current in human atrial myocytes. J Physiol 533:329.
17. Osinski, M.T., et al. 2001. Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A. Mol Pharmacol 59:1044.
18. Sausbier, M., et al. 2000. Mechanisms of NO/cGMP-dependent vasorelaxation. Circ Res 87:825.
19. Hofmann, F., et al. 2000. Rising behind NO: cGMP-dependent protein kinases. J Cell Sci 113:1671.
20. Yan, C., et al. 2003. Functional interplay between angiotensin II and nitric oxide: Cyclic GMP as a key mediator. Arterioscler Thromb Vasc Biol 23:26.
21. Polson, J.B., and S.J. Strada. 1996. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol 36:403.
22. Chiu, P.J., et al. 1988. Comparative effects of vinpocetine and 8-Br-cyclic GMP on the contraction and 45Ca-fluxes in the rabbit aorta. Am J Hypertens 1:262.
23. Beavo, J.A. 1995. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 75:725.
24. Sonnenburg, W.K., et al. 1995. Identification of inhibitory and calmodulin-binding domains of the PDE1A1 and PDE1A2 calmodulin-stimulated cyclic nucleotide phosphodiesterases. J Biol Chem 270:30989.
25. Loughney, K., et al. 1996. Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases. J Biol Chem 271:796.
26. Rybalkin, S.D., et al. 1997. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest 100:2611.
27. Kim, D., et al. 2001. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 104:2338.
28. Jaiswal, R.K. 1992. Endothelin inhibits the atrial natriuretic factor stimulated cGMP production by activating the protein kinase C in rat aortic smooth muscle cells. Biochem Biophys Res Commun 182:395.
29. Molina, C.R., et al. 1987. Effect of in vivo nitroglycerin therapy on endothelium-dependent and independent vascular relaxation and cyclic GMP accumulation in rat aorta. J Cardiovasc Pharmacol 10:371.
30. Leroy, M.J., et al. 1996. Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells. Biochemistry 35:10194.
31. Choi, Y.H., et al. 2001. Identification of a novel isoform ofthe cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes. Biochem J 353:41.
32. Palmer, D., and D.H. Maurice. 2000. Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: Implications for phosphodiesterase 3 inhibition in human cardiovascular tissues. Mol Pharmacol 58:247.
33. Liu, H., and D.H. Maurice. 1998. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: Differential subcellular localization and regulated expression by cyclic AMP. Br J Pharmacol 125:1501.
34. Dunkerley, H.A., et al. 2002. Reduced phosphodiesterase 3 activity and phosphodiesterase 3A level in synthetic vascular smooth muscle cells: Implications for use of phosphodiesterase 3 inhibitors in cardiovascular tissues. Mol Pharmacol 61:1033.
35. Maurice, D.H., and R.J. Haslam. 1990. Nitroprusside enhances isoprenaline-induced increases in cAMP in rat aortic smooth muscle. Eur J Pharmacol 191:471.
36. Tanaka, T., et al. 1988. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 36:313.
37. Lindgren, S.H., et al. 1990. Effects of isozyme-selective phosphodiesterase inhibitors on rat aorta and human platelets: Smooth muscle tone, platelet aggregation and cAMP levels. Acta Physiol Scand 140:209.
38. Conti, M., et al. 2003. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278:5493.
39. Liu, H., and D.H. Maurice. 1999. Phosphorylation-mediated activation and translocation of the cyclic AMP-specific phosphodiesterase PDE4D3 by cyclic AMP-dependent protein kinase and mitogen-activated protein kinases. A potential mechanism allowing for the coordinated regulation of PDE4D activity and targeting. J Biol Chem 274:10557.
40. Liu, H., et al. 2000. Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways. A potential mechanism allowing for the coordinated regulation of PDE4D activity and expression in cells. J Biol Chem 275:26615.
41. Tilley, D.G., and D.H. Maurice. 2002. Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo. Mol Pharmacol 62:497.
42. Rybalkin, S.D., et al. 2003. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93:280.
43. Loughney, K., et al. 1998. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase. Gene 216:139.
44. Stacey, P., et al. 1998. Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem Biophys Res Commun 247:249.
45. Yanaka, N., et al. 1998. Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur J Biochem 255:391.
46. Corbin, J.D., et al. 2000. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem 267:2760.
47. Thomas, M.K., et al. 1990. Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J Biol Chem 265:14964.
48. Rybalkin, S.D., et al. 2002. Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem 277:3310.
49. Aravind, L., and C.P. Ponting. 1997. The GAF domain: An evolutionary link between diverse phototransducing proteins. Trends Biochem Sci 22:458.
50. Rybalkin, S.D., et al. 2003. PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J 22:469.
51. Mullershausen, F., et al. 2001. Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme. J Cell Biol 155:271.
52. Owens, G.K. 1995. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 75:487.
53. Lincoln, T.M., et al. 2001. Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: From the regulation of tone to gene expression. J Appl Physiol 91:1421.
54. Hagiwara, M., et al. 1984. Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem Pharmacol 33:453.
55. Ahn, H.S., et al. 1989. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol 38:3331.
56. Souness, J.E., et al. 1989. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine. Br J Pharmacol 98:725.
57. Boolell, M., et al. 1996. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 78:257.
58. Ballard, S.A., et al. 1998. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 159:2164.
59. Corbin, J.D., et al. 2005. High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun 334:930.
60. Prasad, S., et al. 2000. Sildenafil in primary pulmonary hypertension. N Engl J Med 343:1342.
61. Steiner, M.K., et al. 2005. Pulmonary hypertension: Inhaled nitric oxide, sildenafil and natriuretic peptides. Curr Opin Pharmacol 5:245.
62. Kloner, R.A. 2000. Cardiovascular risk and sildenafil. Am J Cardiol 86:57F.
63. Lugnier, C., and N. Komas. 1993. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: Role in vasodilatation. Eur Heart J 14 (Suppl. I):141.
64. Komas, N., et al. 1991. Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Br J Pharmacol 104:495.
65. Lindgren, S., et al. 1991. Relaxant effects of the selective phosphodiesterase inhibitors milrinone and OPC 3911 on isolated human mesenteric vessels. Pharmacol Toxicol 64:440.
66. Maurice, D.H., et al. 1991. Synergistic actions of nitrovasodilators and isoprenaline on rat aortic smooth muscle. Eur J Pharmacol 192:235.
67. Harris, A.L., et al. 1989. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle. J Pharmacol Exp Ther 249:394.
68. Willette, R.N., et al. 1997. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: Effects of selective phosphodiesterase inhibitors. J Cereb Blood Flow Metab 17:210.
69. Gretarsdottir, S., et al. 2003. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet 35:131.
70. Rybalkin, S.D., et al. 2002. Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. Circ Res 90:151.
71. Nagel, D.J., et al. 2006. Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. Circ Res 98 (6):777.
72. Fukumoto, S., et al. 1999. Distinct role of cAMP and cGMP in the cell cycle control of vascular smooth muscle cells: cGMP delays cell cycle transition through suppression of cyclin D1 and cyclin-dependent kinase 4 activation. Circ Res 85:985.
73. Wharton, J., et al. 2005. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 172:105.
74. Kim, D., et al. 2005. Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: A mechanism by which angiotensin II antagonizes cGMP signaling. J Mol Cell Cardiol 38:175.
75. Souness, J.E., et al. 1992. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem Pharmacol 44:857.
76. Takahashi, S., et al. 1992. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 20:900.
77. Inoue, Y., et al. 2000. Suppression of arterial intimal hyperplasia by cilostamide, a cyclic nucleotide phosphodiesterase 3 inhibitor, in a rat balloon double-injury model. Br J Pharmacol 130:231.
78. Kondo, K., et al. 1999. Milrinone, a phosphodiesterase inhibitor, suppresses intimal thickening after photochemically induced endothelial injury in the mouse femoral artery. Atherosclerosis 142:133.
79. Palmer, D., et al. 1998. Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors. Circ Res 82:852.
80. Munzel, T., et al. 1996. Dissociation of coronary vascular tolerance and neurohormonal adjustments during long-term nitroglycerin therapy in patients with stable coronary artery disease. J Am Coll Cardiol 27:297.
81. Packer, M., et al. 1987. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 317:799.
82. Munzel, T., et al. 1996. New insights into mechanisms underlying nitrate tolerance. Am J Cardiol 77:24C.
83. Munzel, T., et al. 1995. Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci USA 92:5244.
84. De Garavilla, L., et al. 1996. Zaprinast, but not dipyridamole, reverses hemodynamic tolerance to nitroglycerin in vivo. Eur J Pharmacol 313:89.
85. Pagani, E.D., et al. 1993. Reversal of nitroglycerin tolerance in vitro by the cGMP-phosphodiesterase inhibitor zaprinast. Eur J Pharmacol 243:141.
86. Humbert, M., et al. 2004. Treatment of pulmonary arterial hypertension. N Engl J Med 351:1425.
87. Pepke-Zaba, J., et al. 1991. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 338:1173.
88. Taylor, R.W., et al. 2004. Low-dose inhaled nitric oxide in patients with acute lung injury: A randomized controlled trial. JAMA 291:1603.
89. Michelakis, E., et al. 2002. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation 105:2398.
90. Maclean, M.R., et al. 1997. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: Changes in pulmonary hypertension. J Pharmacol Exp Ther 283:619.
91. Wagner, R.S., et al. 1997. Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries. J Pharmacol Exp Ther 282:1650.
92. Ross, R. 1999. Atherosclerosis-an inflammatory disease. N Engl J Med 340:115.
93. Dzau, V.J., et al. 2002. Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies. Nat Med 8:1249.
94. Cayatte, A.J., et al. 1994. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 14:753.
95. Naruse, K., et al. 1994. Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta. PGH2 does not contribute to impaired endothelium-dependent relaxation. Arterioscler Thromb 14:746.
96. Creager, M.A., et al. 1992. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 90:1248.
97. Kawashima, S., et al. 2001. Endothelial NO synthase overexpression inhibits lesion formation in mouse model of vascular remodeling. Arterioscler Thromb Vasc Biol 21:201.
98. Knowles, J.W., et al. 2000. Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-) ApoE(-/-) mice are ameliorated by enalapril treatment. J Clin Invest 105:451.
99. Smith, J.A. 2002. Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication. Clin Cardiol 25:91.
100. Nagaoka, T., et al. 1998. Cyclic nucleotide phosphodiesterase 3 expression in vivo: Evidence for tissue-specific expression of phosphodiesterase 3A or 3B mRNA and activity in the aorta and adipose tissue of atherosclerosis-prone insulin-resistant rats. Diabetes 47:1135.
101. Jurevicius, J., and R. Fischmeister. 1996. cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by beta-adrenergic agonists. Proc Natl Acad Sci USA 93:295.
102. Lehnart, S.E., et al. 2005. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 123:25.